Sangamo Therapeutics to Present Pre-clinical Data From Its Genomic Engineering Platform at the 26th Annual Meeting of the American Society of Gene & Cell Therapy (ASGCT)
02 Mayo 2023 - 3:30PM
Business Wire
Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine
company, today announced that the American Society of Gene &
Cell Therapy (ASGCT) has accepted 14 Sangamo abstracts for
presentation at the 26th ASGCT Annual Meeting being held May 16-20,
2023, in-person in Los Angeles, CA and in a virtual format.
Presentations will focus on the progression of Sangamo’s
pre-clinical programs, including data from the prioritized
neurology programs Nav1.7 and Prion, innovations in the epigenetic
regulation platform and advances in AAV capsid engineering for
delivery.
“The data to be presented at ASGCT reflect important advances in
areas core to our strategy, including epigenetic regulation for
neurological disorders and engineered AAV capsids to potentially
address the issues of delivery,” said Jason Fontenot, Ph.D., Chief
Scientific Officer at Sangamo. “We are excited to share such a
depth of pre-clinical data and look forward to presenting the
innovation that continues to emerge from our research efforts, to
potentially deliver transformative medicines to patients in
need.”
Data to be presented at the ASGCT Annual Meeting include an oral
presentation from Sangamo’s flagship neurology epigenetic
regulation program Nav1.7 to treat chronic neuropathic pain. This
presentation will showcase how Sangamo is using an optimized zinc
finger epigenetic repressor to specifically target and seek to
reduce Nav1.7 expression in dorsal root ganglions to inhibit pain
sensation in diseases of chronic neuropathic pain. Beginning with
Nav1.7-associated small fiber neuralgia, with an estimated
prevalence of at least 43,000 patients in the US, future success in
this indication could subsequently enable the broadened use of this
therapy to other neuropathic pain indications, regardless of the
cause of the pain.
Additional presentations at the ASGCT Annual Meeting will
showcase how Sangamo is advancing its proprietary zinc finger
platform development efforts, including the use of zinc finger
transcriptional regulators designed to reduce the expression of the
Prion protein for the treatment of Creutzfeldt-Jakob disease.
Sangamo will also present data from its proprietary AAV capsid
discovery platform SIFTER™, which enables the engineering of AAV
capsids with the potential for highly improved central nervous
system transduction efficiency, along with broader presentations
showcasing Sangamo’s latest genomic engineering platform
evolution.
ASGCT Annual Meeting Presentations and
Invited Sessions
Epigenetic
Regulation for the Central Nervous System
- Zinc Finger Transcriptional Regulator Mediated Repression of
SCN9A Gene as a Therapeutic Approach for Painful Peripheral
Neuropathies
- Abstract No. 32
- Oral Presentation – May 17; 3:45-4:00 pm PT
- Engineered Zinc Finger Transcriptional Regulators Specifically
Reduce Prion Expression and Extend Survival in an Aggressive Prion
Disease Model
- Abstract No. 490
- Poster Presentation – May 17; 5:30-7:00 pm PT
- Cell-Type Specific Reduction of Prion Expression in Neurons and
Astrocytes Using Engineered Zinc Finger Transcriptional Regulators
- Abstract No. 1561
- Poster Presentation – May 19; 5:30-7:00 pm PT
- Intercellular Zinc Finger Protein Delivery for Cross-Corrective
Epigenetic Regulation in the CNS
- Abstract No. 1485
- Poster Presentation – May 19; 5:30-7:00 pm PT
- Gene Activation Mediated by Zinc Finger Transcriptional
Regulators (ZF-TRs) as a Therapeutic Approach for CNS Disorders
- Abstract No. 1057
- Poster Presentation – May 18; 5:30-7:00 pm PT
Viral Engineering
for the Central Nervous System
- Fitness Maturation of Engineered AAV Capsids STAC-102 and
STAC-103 Enhances Central Nervous System Transduction after CSF
Administration in Cynomolgus Macaques
- Abstract No. 1698
- Poster Presentation – May 19; 5:30-7:00 pm PT
- Evolution of Blood-Brain Barrier Penetrant AAV Capsids in
Non-Human Primates Using a Multiplexed Transcription Dependent
Capsid Engineering Platform
- Abstract No. 1203
- Poster Presentation – May 18; 5:30-7:00 pm PT
- Process and Platform Development for Production and
Purification of CNS-Tropic Engineered AAV Capsids
- Abstract No. 1460
- Poster Presentation – May 19; 5:30-7:00 pm PT
- Strategic Formulation Development for AAV Delivered Gene
Therapies - a Case Study
- Abstract No. 1186
- Poster Presentation – May 18; 5:30-7:00 pm PT
Genomic Engineering
Platform Evolution
- Engineered Zinc Finger Transcriptional Regulators Enable Robust
and Reliable Epigenetic Regulation in the Mouse Brain
- Abstract No. 682
- Poster Presentation – May 17; 5:30-7:00 pm PT
- Zinc Finger-Transcriptional Repressors Against Immune
Checkpoint Molecules to Improve Anti-Tumor Activity of
Gene-Modified T Cells
- Abstract No. 1680
- Poster Presentation – May 19; 5:30-7:00 pm PT
- A Robust and Flexible Baculovirus-Insect Cell System for AAV
Vector Production with Improved Yield, Capsid Ratios and Potency
- Abstract No. 471
- Poster Presentation – May 17; 5:30-7:00 pm PT
Assays to Support
Clinical Programs
- Overcoming the Effect of Previous Enzyme Replacement Therapy on
the Detection of Anti-Transgene Protein Antibodies After Treatment
with Gene Therapy
- Abstract No. 727
- Poster Presentation – May 17; 5:30-7:00 pm PT
- Development of a Competitive Ligand-Binding Assay to Detect
Neutralizing Antibodies Against Chimeric Antigen Receptor of
Regulatory T Cells
- Abstract No. 891
- Poster Presentation – May 18; 5:30-7:00 pm PT
All abstracts for the ASGCT Annual Meeting are available on
ASGCT’s website.
About Sangamo Therapeutics
Sangamo Therapeutics is a clinical-stage biopharmaceutical
company with a robust genomic medicines pipeline. Using
ground-breaking science, including our proprietary zinc finger
genome engineering technology and manufacturing expertise, Sangamo
aims to create new genomic medicines for patients suffering from
diseases for which existing treatment options are inadequate or
currently don’t exist. To learn more, visit www.sangamo.com and
connect with us on LinkedIn and Twitter.
Sangamo Forward-Looking Statements
This press release contains forward-looking statements based on
Sangamo's current expectations. These forward-looking statements
include, without limitation, statements relating to Sangamo’s
technologies, the presentation of data from various therapeutic and
research programs and the potential of these programs to
demonstrate therapeutic benefit and transform the lives of
patients. These statements are not guarantees of future performance
and are subject to certain risks and uncertainties that are
difficult to predict. Factors that could cause actual results to
differ include, but are not limited to, the research development
process, including the results of clinical trials; the regulatory
approval process for product candidates; and the potential for
technological developments that obviate technologies used by
Sangamo. Actual results may differ from those projected in
forward-looking statements due to risks and uncertainties that
exist in Sangamo's operations and business. These risks and
uncertainties are described more fully in our Securities and
Exchange Commission filings and reports, including in our Annual
Report on Form 10-K for the year ended December 31, 2022.
Forward-looking statements contained in this announcement are made
as of this date, and Sangamo undertakes no duty to update such
information except as required under applicable law.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20230502005756/en/
Investor Relations & Media Inquiries Louise Wilkie
ir@sangamo.com media@sangamo.com
Sangamo Therapeutics (NASDAQ:SGMO)
Gráfica de Acción Histórica
De Abr 2024 a May 2024
Sangamo Therapeutics (NASDAQ:SGMO)
Gráfica de Acción Histórica
De May 2023 a May 2024